

We are advancing a deep and broad portfolio of product candidates derived from our four drug classes focused on the treatment of cancer, infectious and rare diseases:

Oncology

Drug Class	Platform	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Rights/Colaborator
mRNA	FixVac (fixed combination of shared cancer antigens)	BNT111	Advanced melanoma (Adjuvant & Metastatic)	██████████	██████████	██████████		Fully-owned
		BNT112	Prostate cancer	██████████	██████████			Fully-owned
		BNT113	HPV16+ head and neck cancer	██████████	██████████	██████████		Fully-owned
		BNT115	Ovarian Cancer	██████████	██████████			Fully-owned
		BNT116	NSCLC	██████████	██████████			Fully-owned
	iNeST (patient specific cancer antigen therapy)	autogene cevumeran (BNT122)	1L melanoma	██████████	██████████	██████████		Genentech ¹ (global 50:50 profit/loss share)
			Adjuvant colorectal cancer	██████████	██████████	██████████		
			Solid tumors Adjuvant PDAC ²	██████████	██████████	██████████		
	Intratumoral Immunotherapy	SAR441000 (BNT131)	Solid tumors (<i>IL-12sc</i> , <i>IL-15sushi</i> , <i>GM-CSF</i> , <i>IFNα</i>)	██████████	██████████			Sanofi (global profit/loss share)
	RiboMabs (mRNA-encoded antibodies)	BNT141	Multiple solid tumors	██████████	██████████			Fully-owned
BNT142		Multiple solid tumors (<i>CD3+CLDN6</i>)	██████████	██████████			Fully-owned	
RiboCytokines (mRNA-encoded cytokines)	BNT151	Multiple solid tumors (<i>Optimized IL-2</i>)	██████████	██████████			Fully-owned	
	BNT152, BNT153	Multiple solid tumors (<i>IL-7, IL-2</i>)	██████████	██████████			Fully-owned	
Cell Therapies	CAR-T Cells	BNT211	Multiple solid tumors (<i>CLDN6</i>)	██████████	██████████			Fully-owned
		BNT212	Pancreatic, other cancers (<i>CLDN18.2</i>)	██████████				Fully-owned
	Neoantigen-based T cell therapy	BNT221	Multiple solid tumors	██████████	██████████			Fully-owned
	TCRs	To be selected	All tumors	██████████				Fully-owned
Antibodies	Next-Gen Immune CP ³ Modulators	GEN1046 (BNT311)	Metastatic NSCLC (<i>PD-L1×4-1BB</i>)	██████████	██████████	██████████		Genmab (global 50:50 profit/loss share)
		GEN1046 (BNT311)	Multiple solid tumors (<i>PD-L1×4-1BB</i>)	██████████	██████████			
		GEN1042 (BNT312)	Multiple solid tumors (<i>CD40×4-1BB</i>)	██████████	██████████			
		GEN1053 (BNT313)	Multiple solid tumors (<i>CD27</i>)	██████████	██████████			
	Targeted Cancer Antibodies	BNT321	Pancreatic cancer (<i>sLea</i>)	██████████	██████████			Fully-owned
SMIM ⁴	Toll-Like Receptor Binding	BNT411	Solid tumors (<i>TLR7</i>)	██████████	██████████			Fully-owned

Infectious Diseases

Drug Class	Product Candidate	Indication (Targets)	Pre-clinical	Phase 1	Phase 2	Phase 3	Commercial	Rights/Colaborator
mRNA	BNT162b2 (Original)	COVID-19	██████████	██████████	██████████	██████████	██████████	Fosun Pharma (China), Pfizer (Global, except China)
	BNT162b2 (Original/Omicron BA.4/BA.5-adapted bivalent)		██████████	██████████	██████████	██████████		
	BNT162b2 (Original/Omicron BA.1-adapted bivalent)		██████████	██████████	██████████	██████████		
	BNT162b4 (T cell enhancing)	COVID-19	██████████					Pfizer
	BNT162b5 (Enhanced spike antigen)	COVID-19	██████████	██████████	██████████			Pfizer
	BNT162b2+BNT161	COVID-19 – Influenza combination	██████████	██████████				Pfizer
	BNT161	Influenza	██████████	██████████	██████████	██████████		Pfizer
	Un-named program	Shingles	██████████					Pfizer
	BNT163	HSV 2	██████████					Fully-owned
	BNT164	Tuberculosis ⁵	██████████					Bill & Melinda Gates Foundation
	BNT165	Malaria	██████████					Fully-owned
	Un-named program	HIV ⁵	██████████					Bill & Melinda Gates Foundation
	Undisclosed programs	Additional mRNA vaccine programs ⁶	██████████					Fully-owned
	Undisclosed programs	Precision antibacterials	██████████					Fully-owned

¹ A member of the Roche Group

² Investigator-initiated Phase 1 trial

³ Checkpoint Inhibitor

⁴ Small Molecule Immunomodulators

⁵ Collaboration with Bill & Melinda Gates Foundation. BioNTech holds worldwide distribution rights except developing countries where BMG holds distribution rights

⁶ University of Pennsylvania collaboration